Onco Wiki / drapeau rouge

L'exposition à la radioiodine thérapeutique (I-131) pour l'ablation différenciée du cancer de la thyroïde (C...

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDRF-IATROGENIC-IODINE131-SECONDARY-PREVENTION
TypeSignal d’alerte
Étatreviewed 2026-05-19 | pending_clinical_signoff
MaladiesDIS-BREAST
SourcesSRC-IARC-100D-IONIZING-RADIATION SRC-NCCN-BREAST-2025

Origine du drapeau rouge

DéfinitionTherapeutic radioiodine (I-131) exposure for differentiated thyroid cancer (DTC) ablation/treatment OR Graves' disease — cumulative doses ≥100 mCi (3.7 GBq) lifetime confer small-but-real increased risk of secondary malignancies. Strongest signal: leukemia (RR ~1.5-2.0 above population baseline; latency 2-10 years), salivary gland cancer (RR ~1.3-2.0; latency 5-15 years), breast cancer in females (RR ~1.2-1.4; lower-quality evidence, dose-dependent), bladder cancer (modest signal). Iodine concentrates in salivary glands + stomach + bladder during excretion; non-target dose drives secondary cancer signal. Risk modestly higher at younger ages of exposure (proliferating tissues more radiosensitive). Prevention- persona RedFlag (§20, v0.3 iatrogenic expansion).
Direction cliniqueenquêter
Catégorieautres

Logique de déclenchement

{
  "any_of": [
    {
      "finding": "iodine_131_cumulative_ge_100mci",
      "value": true
    },
    {
      "finding": "i131_therapy_dtc_completed",
      "value": true
    },
    {
      "finding": "i131_therapy_graves_completed",
      "value": true
    }
  ],
  "type": "lab_value"
}

Notes

Prevention-persona RedFlag for I-131 therapeutic-dose lifetime cumulative exposure. Surveillance: CBC q12mo for leukemia signal (sensitivity modest); breast surveillance per general-population USPSTF unless additional risk factors; oral + salivary symptom awareness. Highest-impact preventive intervention is hydration + lemon-juice sialagogue during I-131 administration (reduces salivary gland uptake) — retrospectively non-actionable for prior exposure. STUB pending two-Co-Lead signoff per CHARTER §6.1 dev-mode.

Utilisé par

Indication